ELITE PHARMACEUTICALS INC Contracts & Agreements
114 Contracts & Agreements
- Business Finance (43 contracts)
- Business Operations (11)
- Human Resources (14)
- Intellectual Property (20)
- Mergers & Acquisitions (1)
- Uncategorized (25)
- Elite Pharmaceuticals, Inc. Restated 2014 Equity Incentive Plan (Filed With SEC on July 1, 2024)
- Asset Purchase Agreement, dated June 17, 2024, by and between the Company and Nostrum Laboratories Inc (Filed With SEC on July 1, 2024)
- Employment Agreement, dated September 5, 2023, between Elite Pharmaceuticals, Inc. and Carter Ward (Filed With SEC on September 7, 2023)
- Employment Agreement, dated April 27, 2023, between Elite Pharmaceuticals, Inc. and Mark Pellegrino (Filed With SEC on May 3, 2023)
- Employment Agreement, dated September 5, 2022, between Elite Pharmaceuticals, Inc. and Kirko Kirkov (Filed With SEC on September 7, 2022)
- Agreement for Sale and Purchase of Real Estate, dated April 8, 2022, by and between Clyde Wesp and Margaret Wesp as trustees of the Wesp Family Joint Living Trust UTD November 19,... (Filed With SEC on August 15, 2022)
- Loan and Security Agreement, dated April 1, 2022, by and among East West Bank, Elite Pharmaceuticals, Inc. and Elite Laboratories, Inc (Filed With SEC on August 15, 2022)
- License, Supply, and Distribution Agreement by and between Elite Pharmaceuticals, Inc. and Lannett Company, Inc, dated October 18, 2021 (Filed With SEC on June 29, 2022)
- License, Supply, and Distribution Agreement by and between Elite Pharmaceuticals, Inc. and Lannett Company, Inc, dated October 18, 2021 (Filed With SEC on June 29, 2022)
- License and Distribution Agreement by and between Elite Pharmaceuticals, Inc. and Dexcel Ltd. (Or Akiva, Israel), dated December 6, 2021 (Filed With SEC on June 29, 2022)
- February 18, 2022 Retention Agreement with Douglas Plassche (Filed With SEC on June 29, 2022)
- License, Supply, and Distribution Agreement by and between Elite Pharmaceuticals and Lannett, Inc., dated July 20, 2021 (Filed With SEC on June 29, 2022)
- Employment Agreement, dated May 5, 2022, between Elite Pharmaceuticals, Inc. and Robert Chen (Filed With SEC on May 11, 2022)
- Master Development and License Agreement for Products Between Elite Pharmaceuticals, Inc. and Mikah Pharma LLC, effective as of June 10, 2021.(Portions of this Agreement have been... (Filed With SEC on August 16, 2021)
- Employment Agreement with Douglas Plassche (Filed With SEC on June 14, 2021)
- June 21, 2019 Retention Agreement with Douglas Plassche (Filed With SEC on June 14, 2021)
- July 29, 2019 Amendment To The License, Supply And Distribution Agreement Between Elite Pharmaceuticals, Inc./Elite Laboratories, Inc. And Lannett Company, Inc. (Portions of this... (Filed With SEC on June 14, 2021)
- Employment Agreement, dated April 26, 2021, between Elite Pharmaceuticals, Inc. and Marc Bregman (Filed With SEC on April 29, 2021)
- Series J Preferred Stock and Series J Common Stock Purchase Warrant anti-dilution waiver (Filed With SEC on August 14, 2020)
- August 1, 2013, Asset Purchase Agreement between the Company and Mikah Pharma LLC (Filed With SEC on July 31, 2020)
- Purchase Agreement, dated July 8, 2020, by and between the Company and Lincoln Park Capital Fund, LLC (Filed With SEC on July 9, 2020)
- Registration Rights Agreement, dated July 8, 2020, by and between the Company and Lincoln Park Capital Fund, LLC (Filed With SEC on July 9, 2020)
- Description of Common Stock (Filed With SEC on June 29, 2020)
- Employment Agreement with Douglas Plassche (Filed With SEC on June 29, 2020)
- June 21, 2019 Retention Agreement with Douglas Plassche (Filed With SEC on June 29, 2020)
- July 29, 2019 Amendment To The License, Supply And Distribution Agreement Between Elite Pharmaceuticals, Inc./Elite Laboratories, Inc. And Lannett Company, Inc. (Portions of this... (Filed With SEC on June 29, 2020)
- August 1, 2018 Amendment to the Glenmark Pharmaceuticals Inc. USA License, Supply and Distribution Agreement (portions of this Agreement have been redacted in compliance with... (Filed With SEC on February 10, 2020)
- License, Supply And Distribution Agreement effective March 6, 2019 by and between Elite Pharmaceuticals, Inc., and Elite Laboratories, Inc. and Lannett Company, Inc., USA... (Filed With SEC on February 10, 2020)
- Asset Purchase Agreement dated November 13, 2019 by and between the Company and Nostrum Laboratories Inc (Filed With SEC on February 10, 2020)
- January 2, 2020 Amendment to the Glenmark Pharmaceuticals Inc. USA License, Supply and Distribution Agreement (portions of this Agreement have been redacted in compliance with... (Filed With SEC on February 10, 2020)
- Asset Purchase Agreement executed January 16, 2020 by and between the Company and Nostrum Laboratories Inc (Filed With SEC on February 10, 2020)
- License, Supply And Distribution Agreement effective April 9, 2019 by and between Elite Pharmaceuticals, Inc., and Elite Laboratories, Inc. and Lannett Company, Inc., USA... (Filed With SEC on June 21, 2019)
- License, Supply And Distribution Agreement effective March 6, 2019 by and between Elite Pharmaceuticals, Inc., and Elite Laboratories, Inc. and Lannett Company, Inc., USA... (Filed With SEC on June 21, 2019)
- Development Agreement effective December 3, 2018 by and between Mikah Pharma LLC and Elite Laboratories, Inc. (portions of this Agreement have been redacted in compliance with... (Filed With SEC on June 21, 2019)
- August 1, 2013, Asset Purchase Agreement between the Company and Mikah Pharma LLC (Filed With SEC on August 30, 2018)
- May 29, 2018 License, Manufacturing and Supply Agreement with Glenmark Pharmaceuticals Inc. USA. Confidential portions of this exhibit have been redacted and filed separately with... (Filed With SEC on June 14, 2018)
- MASTER DEVELOPMENT AND LICENSE AGREEMENTFOR PRODUCTS BETWEEN ELITE PHARMACEUTICALS, INC. AND SUNGEN (Filed With SEC on August 9, 2017)
- SECOND AMENDMENT TO THE MASTER DEVELOPMENT AND LICENSE AGREEMENTFOR PRODUCTS BETWEEN ELITE PHARMACEUTICALS, INC. AND SUNGEN PHARMA, LLC (Filed With SEC on August 9, 2017)
- FIRST AMENDMENT TO THE MASTER DEVELOPMENT AND LICENSE AGREEMENTFOR PRODUCTS BETWEEN ELITE PHARMACEUTICALS, INC. AND SUNGEN PHARMA, LLC (Filed With SEC on August 9, 2017)
- ASSET PURCHASE AGREEMENT (Filed With SEC on June 14, 2017)
- ELITE PHARMACEUTICALS, INC. AND ELITELABORATORIES, INC. SECURED NOTE DUE 2020 (Filed With SEC on June 14, 2017)
- ANDA SECURITY AGREEMENT (Filed With SEC on June 14, 2017)
- ASSIGNMENT AGREEMENT (Filed With SEC on June 14, 2017)
- ASSIGNMENT AGREEMENT (Filed With SEC on June 14, 2017)
- SUPPLY AND DISTRIBUTION AGREEMENT (Filed With SEC on June 14, 2017)
- MANUFACTURING AND SUPPLY AGREEMENT (Filed With SEC on June 14, 2017)
- PURCHASE AGREEMENT (Filed With SEC on May 2, 2017)
- REGISTRATION RIGHTS AGREEMENT (Filed With SEC on May 2, 2017)
- COMMON STOCK PURCHASE WARRANT ElitePharmaceuticals, inc. (Filed With SEC on April 28, 2017)
- EXCHANGE AGREEMENT (Filed With SEC on April 28, 2017)
- MASTER DEVELOPMENT AND LICENSE AGREEMENTFOR PRODUCTS BETWEEN ELITE PHARMACEUTICALS, INC. AND SUNGEN (Filed With SEC on November 9, 2016)
- Signature page to follow 165 Ludlow Avenue • Northvale, NJ 07647• Ph: (201 ###-###-#### • Fax: (201 ###-###-#### www.elitepharma.com (Filed With SEC on November 9, 2016)
- 165 Ludlow Avenue • Northvale, NJ 07647• Ph: (201 ###-###-#### • Fax: (201 ###-###-#### www.elitepharma.com (Filed With SEC on November 9, 2016)
- AMENDMENT 1 TO EMPLOYMENT AGREEMENT (Filed With SEC on January 29, 2016)
- LICENSE AGREEMENT (Filed With SEC on June 15, 2015)
- 165 Ludlow Avenue• Northvale, NJ 07647 • Ph: (201 ###-###-#### • Fax: (201 ###-###-#### www.elitepharma.com {***} Confidentialportions of this exhibit have been redacted and... (Filed With SEC on February 17, 2015)
- First Amendment to Loan Agreement (Filed With SEC on February 17, 2015)
- TERMINATION OF DEVELOPMENT AND LICENSEAGREEMENT FOR MIKAH-001 BETWEEN ELITE PHARMACEUTICALS , INC. AND MIKAH PHARMA LLC AND TRANSFER OF PAYMENT (Filed With SEC on February 17, 2015)
- EMPLOYMENT AGREEMENT (Filed With SEC on November 14, 2014)
- PURCHASE AGREEMENT (Filed With SEC on April 14, 2014)
- REGISTRATION RIGHTS AGREEMENT (Filed With SEC on April 14, 2014)
- CERTIFICATE OF DESIGNATION of SERIES I CONVERTIBLE PREFERRED STOCK of ELITE PHARMACEUTICALS, INC., (Pursuant to Section 78.1955 of the Nevada Revised Statutes) (Filed With SEC on February 7, 2014)
- ELITEPHARMACEUTICALS, INC. incorporatedunder the laws of the state of nevada SERIES I CONVERTIBLE PREFERRED STOCK (Filed With SEC on February 7, 2014)
- AMENDMENT TO THE AUGUST 1, 2013 SECURED CONVERTIBLENOTE TO MIKAH PHARMA LLC DUE AUGUST 1, 2016IN THE PRINCIPAL AMOUNT OF $10,000,000 (Filed With SEC on February 7, 2014)
- AMENDMENT TO THE NOVEMBER 21, 2013 SECURED CONVERTIBLENOTE TO JERRY TREPPEL DUE NOVEMBER 21, 2016 IN THE PRINCIPALAMOUNT OF $600,000 (Filed With SEC on February 7, 2014)
- ELITE PHARMACEUTICALS, INC. AND ELITELABORATORIES, INC. CONVERTIBLE NOTE DUE 2016 (Filed With SEC on November 26, 2013)
- LOAN AGREEMENT (Filed With SEC on November 14, 2013)
- MANUFACTURING AND LICENSE AGREEMENT Between Elite Pharmaceuticals, Inc. and Epic Pharma LLC (Filed With SEC on November 14, 2013)
- CONFIDENTIAL MASTER SERVICES AGREEMENT (Filed With SEC on November 14, 2013)
- Exhibit 10. 12 SCHEDULE 1 ABBREVIATED NEW DRUG APPLICATIONS (Filed With SEC on August 14, 2013)
- Exhibit 10.15 (Filed With SEC on August 14, 2013)
- Amendment No. 2 to Treppel Loan Agreement (Filed With SEC on August 6, 2013)
- ASSET PURCHASE AGREEMENT (Filed With SEC on August 5, 2013)
- ELITE PHARMACEUTICALS, INC. AND ELITELABORATORIES, INC. SECURED CONVERTIBLE NOTE DUE 2016 (Filed With SEC on August 5, 2013)
- ANDA SECURITY AGREEMENT (Filed With SEC on August 5, 2013)
- EMPLOYMENT AGREEMENT (Filed With SEC on August 5, 2013)
- ELITE PHARMACEUTICALS, INC. CERTIFICATE OF DESIGNATIONS OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES G PREFERRED STOCK Pursuant to NRS 78.1955 (Filed With SEC on April 22, 2013)
- ELITE PHARMACEUTICALS, INC. incorporatedunder the laws of the state of nevada SERIES G CONVERTIBLE PREFERRED STOCK (Filed With SEC on April 22, 2013)
- PURCHASE AGREEMENT (Filed With SEC on April 22, 2013)
- REGISTRATIONRIGHTS AGREEMENT (Filed With SEC on April 22, 2013)
- Amendment No. 1 to Treppel Loan Agreement (Filed With SEC on December 10, 2012)
- Exhibit 10.6 (Filed With SEC on November 14, 2012)
- Exhibit 10. 77 MASTER DEVELOPMENT AND LICENSE AGREEMENTFOR PRODUCT BETWEEN ELITE PHARMACEUTICALS, INC. AND {***} (Filed With SEC on June 29, 2012)
- LOAN AGREEMENT (Filed With SEC on June 13, 2012)
- AMENDMENT AGREEMENT (Filed With SEC on February 29, 2012)
- AGREEMENT AND PLAN OF MERGER By and Between ELITE PHARMACEUTICALS, INC. (a Nevada corporation) and ELITE PHARMACEUTICALS INC. (a Delaware corporation) AGREEMENT AND PLAN OF MERGER (Filed With SEC on January 9, 2012)
- Elite Pharmaceuticals, Inc. Warrant To Purchase Common Stock (Filed With SEC on January 5, 2012)
- SECURITIES PURCHASE AGREEMENT (Filed With SEC on January 5, 2012)
- AMENDMENT TO THE MASTER DEVELOPMENT AND LICENSE AGREEMENT FOR {***} BETWEEN ELITE PHARMACEUTICALS, INC. AND MIKAH PHARMA, LLC (Filed With SEC on November 14, 2011)
- MANUFACTURING AND SUPPLY AGREEMENT (Filed With SEC on June 29, 2011)
- MANUFACTURING AND SUPPLY AGREEMENT (Filed With SEC on June 29, 2011)
- Execution Copy Settlement Agreement (Filed With SEC on March 17, 2011)
- DEVELOPMENT AND SUPPLYAGREEMENT FOR GENERIC{***} BETWEEN ELITEPHARMACEUTICALS AND HI-TECH PHARMACAL CO.INC. (Filed With SEC on January 10, 2011)
- ASSET PURCHASEAGREEMENT (Filed With SEC on November 15, 2010)
- ASSET PURCHASEAGREEMENT (Filed With SEC on November 15, 2010)
- MASTER DEVELOPMENT ANDLICENSE AGREEMENT FOR {***} BETWEEN ELITE PHARMACEUTICALS, INC. AND MIKAHPHARMA, LLC (Filed With SEC on November 15, 2010)
- PURCHASEAGREEMENT between ELITEPHARMACEUTICALS, INC. and EPICPHARMA, LLC Dated asof September 10, 2010 (Filed With SEC on November 15, 2010)
- LICENSEAGREEMENT (Filed With SEC on November 15, 2010)
- MANUFACTURINGAND SUPPLY AGREEMENT (Filed With SEC on November 15, 2010)
- Proprietary Rights Agreement (see attached) (Filed With SEC on July 8, 2009)
- 210,000,000 SHARES OF COMMON STOCK PAR VALUE $0.01 PER SHARE 4,483,442 SHARES OF PREFERRED STOCK PAR VALUE $0.01 PER SHARE *S*P*E*C*I*M*E*N (Filed With SEC on June 5, 2009)
- WARRANT TO PURCHASE 40,000,000 SHARES OF COMMON STOCK OF ELITE PHARMACEUTICALS, INC. Exercise Price: $0.0625 per share, subject to adjustment as provided below (the "Exercise... (Filed With SEC on June 5, 2009)
- - 2 - (Filed With SEC on June 5, 2009)
- Execution Version (Filed With SEC on May 6, 2009)
- STRATEGIC ALLIANCE AGREEMENT (Filed With SEC on March 23, 2009)
- INTRODUCTION (Filed With SEC on December 4, 2008)
- [SIGNATURE PAGE FOLLOWS] 2 (Filed With SEC on November 14, 2008)
- BACKGROUND (Filed With SEC on November 6, 2008)
- BACKGROUND (Filed With SEC on November 3, 2008)
- INTRODUCTION (Filed With SEC on November 3, 2008)
- BACKGROUND (Filed With SEC on October 21, 2008)
- INTRODUCTION (Filed With SEC on October 21, 2008)
- R E C I T A L S: (Filed With SEC on January 9, 2008)
- COMMON STOCK PURCHASE WARRANT To Purchase 75,000 Shares of Common Stock of ELITE PHARMACEUTICALS, INC. (Filed With SEC on November 14, 2007)
